Please read and acknowledge the form below if you want access www.m4bteam.com.

I am not a law enforcement officer nor am I affiliated with a law enforcement officer or agency. I am not accessing this site to gain information to use against the website operators it's affiliates or any other person or entity in any conceivable manner.

I will hold the operators of this website, or anyone associated with this website harmless for any information I find herein.

I know and understand the laws in my country and state with regards to purchasing prescription medication and agree to hold the owners and operators of this site harmless for my actions.

I posses valid prescription for ordered medicaments and im using them under doctor's control.

I posses knowlage about side effects of using anabolic steroids when they are used for different then prescripted puropose.

IMPORTANT: IF YOU ARE AOL USER ( your email address is for instance [email protected]) PLEASE SET UP A NEW FREE EMAIL USING ANY OTHER MAIL SITE AVAILABLE AROUND (LIKE YAHOO, GMAIL, HUSHMAIL, ETC) BECAUSE AOL BLOCKS EMAILS SENT FROM OUR BUSINESS.

IF YOU TRY ORDERING USING AOL EMAIL, YOU WILL NOT RECEIVE ANY MESSAGE FROM US. SORRY FOR YOUR INCONVIENCE WE ARE NOT RESPONSIBLE FOR THIS.

1,244.2€991.8€

ORDERING THIS SET YOU ALSO GET FREE OF CHARGE 2 x 10 ml VIALS OF TESTOSTERONE ENANTHATE 300mg or Test Propionate 100mg

Human Growth Hormone, Blue Top, 191aa

Clinical pharmacology

A: Tissue Growth
1. Skeletal Growth: GH stimulates skeletal growth in children with growth failure due to a lack of adequate secretion of endogenous GH or secondary to chronic renal insufficiency and in patients with Turner's syndrome.
2. Cell Growth: Treatment with rhGH results in an increase in both the number and the size of skeletal muscle cells.
3. Organ Growth: GH influences the size of internal organs, including kidneys and increases red cell mass. Treatment of hypophysectomized or genetic dwarf rat with GH results in organ growth that is proportional to the overall body growth.
B: Protein Metabolism
Linear growth is promoted in part by GH stimulated protein synthesis. This is reflected by nitrogen retention as demonstrated by a decline in urinary nitrogen excretion and blood urea nitrogen during GH therapy.
C: Carbohydrate Metabolism
Hypopituitary children sometimes experience fasting hypoglycemia that may be improved by treatment with rhGH. Large dose of rhGH may impair glucose tolerance.
D: Lipid Metabolism
In-growth-hormone-deficient patients administration of rhGH has resulted in lipid mobilization, reduction in body fat stores; and increased plasma fatty acids.
E: Mineral Metabolism
Retention of sodium, potassium and phosphorus is induced by administration of rhGH.
Absorption, distribution and excretion
Subcutaneous and intramuscular pharmacokinetic profiles of rhGH are similar, and usually the subcutaneous administration results in a higher serum GH level but produces the same IGF-I level, compared with intramuscular route. Peak plasma levels are reached in 3-5 hours following administration and the elimination half life is 2-3 hours. The elimination takes place in liver and kidneys, faster in adults than in children, less GH is detected in urine after metabolism. Serum GH is not influenced by the time selected for injection in a day and endogenous peak GH level is reached usually following the slow-wave sleeping phase, so the administration at night before sleep is recommended.

Indications

Conventional indications:
1. Long-term treatment of children who have a growth failure due to a lack of endogenous growth hormone secretion.
2. Treatment of children who have growth failure associated with chronic renal insufficiency up to the time of renal transplant.
3. Patients suffered from Turner�s syndrome.

Unconventional indications:

Supplement in aging, and in management of cachexia secondary to some chronic diseases; also in restoration of positive nitrogen balance due to burn or surgery, etc.

Contraindications

1. Should not be used in subjects with closed epiphysis.
2. Should not be used in patients with active neoplasia.
3. Should not be used in pregnant women and nursing mothers.

Precautions

Prior to the administration, a competent medical expert is needed for intensive guidance.

1. For diabetic patients, the dose of antihyperglycemic may be adjusted regularly.
2. Patients with growth hormone deficiency secondary to an intracranial neoplasm or lesion should be examined frequently for progression or recurrence of the underlying disease.
3. Concomitant glucocorticoid therapy may inhibit the growth hormone promoting effects; Patients with coexisting ACTH deficiency should have their glucocorticoed replacement dose carefully adjusted to avoid an inhibitory effect on growth treatment.
4. Hypothyroidism may develop during administration of rhGH, patients should have periodic thyroid function tests and treated with thyroid hormone when indicated.

Dosage and Administration

The dosage should be individualized.

Generally recommended dosage for long-term treatment of children who have growth failure due to hGH deficiency.

For subcutaneous injection:
0.1-0.2 IU/kg body weight, 6-7 times a week, or 2-3 IU/m2 body surface area 3 times a week.

For intramuscular injection:
0.2-0.24 IU/kg body weight, 3 times a week, or 4-6 IU/ m2 body surface area 3 times a week.

For other application, please consult your medical experts.

Dissolution procedure

1. Use a syringe and needle for injection. Before injection, the rubber closures should be wiped with an antiseptic solution to prevent contamination after repeated needle insertions. Push the needle through the rubber closures on the top of the vial with diluent, draw up the diluent.
2. Pull out the needle, Take the vial with dry powder push the needle through the rubber closure and inject the diluent into the vial aiming the stream of liquid against the glass wall.
3. Dissolve the dry powder completely by gently turning the vial upside and down several times. Do not shake the vial vigorously.

Adverse reactions and Storage

Adverse reactions

Injected site discomfort and mild transient peripheral edema have been reported at early stage following administration, but occurrence rates are decreases as the administration continues.

Storage

The dry powder is stable until the date of expiry indicated on the label, provided it is kept in a cool place (2-8 o C). The dissolution of the dry powder, the solution is stable for 24 hours if kept at 2-8 o C. Avoid freezing, avoid direct sunlight.